News

Equinox Gold: Deserves Trading Below Book Value While Gold Shines
Equinox Gold’s weak operations and risky regions justify its discount despite gold’s rise and peer comparison. Find out why ...
Iovance Biotherapeutics, Inc.: Iovance Announces Five-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previousl ...